Eris Lifesciences Limited Asset Resilience Ratio

Latest as of March 2026: 0.29%

Eris Lifesciences Limited asset resilience ratio. Eris Lifesciences Limited (ERIS) has an Asset Resilience Ratio of 0.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Eris Lifesciences Limited fund operations to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Rs216.40 Million
≈ $2.34 Million USD Cash + Short-term Investments

Total Assets

Rs73.66 Billion
≈ $796.55 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Eris Lifesciences Limited (2012–2026)

Asset resilience ratio of Eris Lifesciences Limited from 2012 to 2026. This chart shows how Eris Lifesciences Limited's Asset Resilience Ratio has changed over time. Read Eris Lifesciences Limited total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Eris Lifesciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ERIS asset base.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs216.40 Million 0.29%
Total Liquid Assets Rs216.40 Million 0.29%

Asset Resilience Insights

  • Limited Liquidity: Eris Lifesciences Limited maintains only 0.29% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Eris Lifesciences Limited Industry Peers by Asset Resilience Ratio

Compare Eris Lifesciences Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
Drug Manufacturers - Specialty & Generic 26.45%
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
Drug Manufacturers - Specialty & Generic 11.84%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%
Bide Pharmatech Co. Ltd. A
SHG:688073
Drug Manufacturers - Specialty & Generic 9.46%
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
Drug Manufacturers - Specialty & Generic 20.61%
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
Drug Manufacturers - Specialty & Generic 30.38%
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
Drug Manufacturers - Specialty & Generic 0.42%

Eris Lifesciences Limited Asset Resilience Ratio by Year (2012–2026)

Eris Lifesciences Limited asset resilience ratio by year from 2012 to 2026. The table below shows the annual Asset Resilience Ratio data for Eris Lifesciences Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2026-03-31 0.29% Rs216.40 Million
≈ $2.34 Million
Rs73.66 Billion
≈ $796.55 Million
+0.22pp
2025-03-31 0.07% Rs50.00 Million
≈ $540.73K
Rs70.33 Billion
≈ $760.61 Million
-17.59pp
2024-03-31 17.66% Rs12.45 Billion
≈ $134.60 Million
Rs70.49 Billion
≈ $762.30 Million
+16.75pp
2023-03-31 0.91% Rs332.21 Million
≈ $3.59 Million
Rs36.67 Billion
≈ $396.61 Million
-6.26pp
2022-03-31 7.17% Rs1.63 Billion
≈ $17.62 Million
Rs22.72 Billion
≈ $245.72 Million
+6.33pp
2021-03-31 0.84% Rs153.99 Million
≈ $1.67 Million
Rs18.35 Billion
≈ $198.42 Million
-3.98pp
2020-03-31 4.82% Rs747.81 Million
≈ $8.09 Million
Rs15.52 Billion
≈ $167.88 Million
-15.45pp
2019-03-31 20.27% Rs3.15 Billion
≈ $34.06 Million
Rs15.54 Billion
≈ $168.02 Million
+13.85pp
2018-03-31 6.42% Rs937.89 Million
≈ $10.14 Million
Rs14.60 Billion
≈ $157.90 Million
-33.90pp
2017-03-31 40.33% Rs2.58 Billion
≈ $27.95 Million
Rs6.41 Billion
≈ $69.32 Million
+24.72pp
2016-03-31 15.61% Rs653.20 Million
≈ $7.06 Million
Rs4.19 Billion
≈ $45.27 Million
-3.77pp
2015-03-31 19.38% Rs692.40 Million
≈ $7.49 Million
Rs3.57 Billion
≈ $38.64 Million
-5.37pp
2014-03-31 24.75% Rs669.64 Million
≈ $7.24 Million
Rs2.71 Billion
≈ $29.26 Million
-2.32pp
2013-03-31 27.07% Rs465.00 Million
≈ $5.03 Million
Rs1.72 Billion
≈ $18.58 Million
+13.88pp
2012-03-31 13.18% Rs134.52 Million
≈ $1.45 Million
Rs1.02 Billion
≈ $11.04 Million
--
pp = percentage points

About Eris Lifesciences Limited

NSE:ERIS India Drug Manufacturers - Specialty & Generic
Market Cap
$1.77 Billion
Rs163.21 Billion INR
Market Cap Rank
#6336 Global
#290 in India
Share Price
Rs1177.70
Change (1 day)
+1.51%
52-Week Range
Rs1095.50 - Rs1701.30
All Time High
Rs1847.70
About

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more